17.10.2012 - U.S. drug reviewers flagged several safety concerns, including possible cancer risks, related to Sanofi and Isis Pharmaceuticals's lipid disorder drug Kynamro, sending Isis's...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)